Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

TScan Therapeutics (TCRX) Revenue (2020 - 2025)

TScan Therapeutics (TCRX) has disclosed Revenue for 6 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • Quarterly Revenue rose 286.02% to $2.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $10.3 million through Dec 2025, up 266.65% year-over-year, with the annual reading at $10.3 million for FY2025, 266.65% up from the prior year.
  • Revenue for Q4 2025 was $2.6 million at TScan Therapeutics, up from $2.5 million in the prior quarter.
  • The five-year high for Revenue was $7.2 million in Q4 2023, with the low at $536000.0 in Q2 2024.
  • Average Revenue over 5 years is $2.8 million, with a median of $2.9 million recorded in 2021.
  • The sharpest move saw Revenue surged 731.72% in 2021, then crashed 90.78% in 2024.
  • Over 5 years, Revenue stood at $2.9 million in 2021, then grew by 8.44% to $3.1 million in 2022, then skyrocketed by 132.99% to $7.2 million in 2023, then plummeted by 90.78% to $665000.0 in 2024, then soared by 286.02% to $2.6 million in 2025.
  • According to Business Quant data, Revenue over the past three periods came in at $2.6 million, $2.5 million, and $3.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.